Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival

World Journal of Surgery

Volumn 31, Issue 7, 2007, Pages 1438-1444

  Hsu, Kai Hsi ^a,b   Tsai, Hung Wen ^c   Shan, Yan Shen ^c   Lin, Pin Wen ^c  

^a Tainan Hospital   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ORGANIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 34250623276     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-9088-1     Document Type: Article

References (42)

1. Screaton GR, Bell MV, Jackson DG, et al. (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160-12164
2. Trowbridge I, Lesley J, Schulte R, et al. (1982) Biochemical characterization and cellular distribution of a polymorphic, murine cellsurface glycoprotein expressed in lymphoid tissues. Immunogenetics 15:299-312
3. Naor D, Sionov RV, Ish-Shalom D. (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241-319
4. Tolg C, Hoffman M, Herrlich P, et al. (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acid Res 21:1225-1229
5. Soukka T, Salmi M, Joensuu H, et al. (1997) Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 57:2281-2289
6. Aruffo A, Stamenkovic I, Melnick M, et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61:1303-1313
7. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211-231
8. Sneath RJ, Mangham DC (1998) The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51:191-200
9. Gunthert U, Hofmann M, Rudy W, et al. (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13-24
10. Granberg D, Wilander E, Oberg K, et al. (1999) Decreased survival in patients with CD44-negitive typical bronchial carcinoid tumors. Int J Cancer 84:484-488
11. Humphrey G, Hazel DL, MacLennan K, et al. (1999) Expression of CD44 by rhabdomyosarcoma: a new prognostic marker? Br J Cancer 80:918-921
12. Kahara N, Ozaki T, Doi T, et al. (2000) CD44 expression in soft tissue sarcomas. Virchows Arch 436:574-578
13. Poncelet C, Walker F, Madelenat P, et al. (2001) Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 32:1190-1196
14. Peiper M, Sato T, Zurakowski D (2004) CD44s expression is associated with improved survival in soft tissue sarcoma. Anticancer Res 24:1053-1056
15. Diaz LK, Zhou X, Wright ET, et al. (2005) CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11:3309-3314
16. Lai CH, Shan YS, Sy ED, et al. (2005) The significance of CD44 expression in gastrointestinal neuroendocrine tumors. Hepatogastroenterology 52:1071-1076
17. Kindblom LG, Remotti HE, Aldenborg F, et al. (1998) Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269
18. Hirota S, Isozaki K, Moriyama Y, et al. (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279:577-580
19. Demetri GD, Mehren MV, Blanke CD, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
20. Savage DG, Antman KH (2002) Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346:683-693
21. Rubin BP, Singer S, Tsao C, et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121
22. Roberts PJ, Eisenberg B (2002) Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 38:S37-S38
23. Nilsson B, Bumming P, Meis-Kindblom JM, et al. (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103:821-829
24. Iesalnieks I, Rummele P, Dietmaier W, et al. (2005) Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol 124:740-748
25. Fletcher CD, Berman JJ, Corless C, et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465
26. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507-519
27. Ropponen KM, Eskelinen MJ, Lipponen PK, et al. (1998) Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33:301-309
28. Wielenga VJ, van der Neut R, Offerhaus GJ, et al. (2000) CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value. Adv Cancer Res 77:169-187
29. Bankfalvi A, Terpe HJ, Breukelmann D, et al. (1998) Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 33:107-116
30. Sun X, Gong Y, Talamonti MS, et al. (2002) Expression of cell adhesion molecule, CD44s and E-cadherin, and microvessel density in carcinoid tumors. Modern Pathol 15:1333-1338
31. Montgomery E, Abraham SC, Fisher C, et al. (2004) CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 28:168-177
32. Sugino T, Gorham H, Yoshida K, et al. (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 149:873-882
33. Okamoto I, Tsuiki H, Kenyon LC, et al. (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441-447
34. Heinrich MC, Corless CL (2005) Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol 90:195-207
35. Yan H, Marchettini P, Acherman YI, et al. (2003) Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 26:221-228
36. Kwon SJ (2001) Korean Gastric Cancer Study Group. Surgery and prognostic factors for gastric stromal tumor. World J Surg 25:290-295
37. Steinert DM, Oyarzo M, Wang X, et al. (2006) Expression of Bcl-2 in gastrointestinal stromal tumors correlation with progression-free survival in 81 patients treated with Imatinib Mesylate. Cancer 106:1617-1623
38. Stewart AE, Heslin MH, Arch J, et al. (2006) Cyclooxygenase-2 expression and clinical outcome in gastrointestinal stromal tumors. J Gastrointest Surg 10:315-319
39. Takahashi R, Tanaka S, Kitadai Y, et al. (2003) Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64:266-274
40. Dei Tos AP (2003) The reappraisal of gastrointestinal stromal tumors: from stout to the KIT revolution. Virchows Arch 442:421-428
41. Rudolph P, Gloeckner K, Parwaresch R, et al. (1998) Immunophenotype, proliferation, DNA-ploidy, and biological behavior of gastrointestinal stromal tumors: a multivariate clinicopathological study. Hum Pathol 29:791-800
42. Singer S, Rubin BP, Lux ML, et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20:3898-3905